Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
An update from TOT BIOPHARM International Co. Ltd. ( (HK:1875) ) is now available.
TOT BIOPHARM International Co. Ltd. reported a 13% year-on-year increase in revenue for the first quarter of 2025, reaching RMB252,200 thousand. This growth is primarily due to the steady increase in sales of its self-developed products. Despite the revenue growth, the company’s net income decreased compared to the same period last year, highlighting potential challenges in maintaining profitability. Stakeholders are advised to exercise caution as the company’s financial results have shown fluctuations in the past and may continue to do so.
The most recent analyst rating on (HK:1875) stock is a Buy with a HK$3.0000 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.
More about TOT BIOPHARM International Co. Ltd.
TOT BIOPHARM International Co. Ltd. operates in the biopharmaceutical industry, focusing on the development and commercialization of oncology drugs. The company is known for its self-developed products, which contribute significantly to its revenue.
Average Trading Volume: 179,945
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.45B
For a thorough assessment of 1875 stock, go to TipRanks’ Stock Analysis page.